Point of Care Network (POCN), an NP and PA network, today released a new survey featuring how 153 NPs and PAs are engaging with life sciences companies in light of the COVID-19 pandemic. Some of the information touched on was the shifting roles and responsibilities of NPs and PAs, ideas to support them to improve patient care, and how they would like to receive communications.
The survey found that COVID-19 has significantly shifted both NPs’ and PAs’ roles and responsibilities. Not surprisingly, 95 percent of the respondents reported that telehealth has had a large impact on their interactions with patients.
Pre-pandemic, in a previous POCN survey, nearly 59 percent of the respondents used conferences to receive information from life sciences companies. In light of newly cancelled events, NPs and PAs are embracing virtual communications even more. In this new survey, the overwhelming majority wants to be reached electronically, through emails, journals, KOL webinars, and are open to virtual rep visits. Finally, the types of conference-style information they want to see most from life sciences companies are prescribing and treatment guidelines, patient assistance programs, disease info, samples, and copay cards.
For the full survey, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.